{"nctId":"NCT00539032","briefTitle":"Immunology and Safety of Menactra® in Children in Saudi Arabia","startDateStruct":{"date":"2007-09"},"conditions":["Meningitis","Meningococcemia"],"count":238,"armGroups":[{"label":"Group 1: Menactra® Booster Group","type":"EXPERIMENTAL","interventionNames":["Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate"]},{"label":"Group 2: Menactra® Primary Vaccine (Control) Group","type":"EXPERIMENTAL","interventionNames":["Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate"]}],"interventions":[{"name":"Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","otherNames":["Menactra® Vaccine"]},{"name":"Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","otherNames":["Menactra® Vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Healthy, as determined by medical history and physical examination.\n* Aged between 5 to 8 years on the day of inclusion (from 5th birthday to 1 day before 9th birthday inclusive).\n* For the Booster Group , two doses of a quadrivalent (A, C, Y, W-135) meningococcal polysaccharide vaccine received before age 2 years\n* For the Control Group , no previous history of any meningococcal vaccination\n* Informed consent form signed by the parent(s) or other legal representative\n* Able to provide a vaccination log or has available vaccination record in the Health Center.\n* Able to attend all scheduled visits and to comply with all trial procedures\n\nExclusion Criteria :\n\n* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc.)\n* Known or suspected impairment of immunologic function.\n* Acute medical illness with or without fever within the last 72 hours or a oral temperature ≥ 37.5°C at the time of inclusion.\n* Administration of immune globulin or other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the trial vaccine. Individuals on a tapering dose schedule of oral steroids lasting \\< 7 days may be included in the trial provided that they have not received more than one course within the last two weeks prior to enrollment.\n* Oral or injected antibiotic therapy within the 72 hours prior to vaccination.\n* Received any vaccine in the 14-day period prior to trial vaccination, or scheduled to receive any vaccination during the 14-day period after trial vaccination.\n* Previous history of documented invasive meningococcal disease.\n* For the Control Group, previous history of any meningococcal vaccination.\n* Systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or a vaccine containing the same substances.\n* Participation in another clinical trial in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Any condition, which, in the opinion of the investigator, would pose a health risk to the subject, or interfere with the evaluation of the vaccine.\n* Personal or family history of Guillain Barré syndrome.","healthyVolunteers":true,"sex":"ALL","minimumAge":"5 Years","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Reporting At Least 1 Solicited Injection Site or Systemic Reaction Post-Vaccination With Menactra®","description":"Solicited injection Site reactions: Pain, erythema, and swelling; Solicited systemic reactions: Fever, headache, malaise and myalgia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) as Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168.9","spread":null},{"groupId":"OG001","value":"196.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6991.7","spread":null},{"groupId":"OG001","value":"8263.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167.2","spread":null},{"groupId":"OG001","value":"512.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2120.2","spread":null},{"groupId":"OG001","value":"2558.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2387.7","spread":null},{"groupId":"OG001","value":"2763.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With ≥ 4-Fold Rise in Titers for the Menactra® Vaccine Serogroups A, C, Y, and W-135.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":151},"commonTop":["Injection site pain","Myalgia","Malaise","Pyrexia","Injection site swelling"]}}}